Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering Plans For Possible Clarinex Switch By Readying OTC Division

This article was originally published in The Tan Sheet

Executive Summary

Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay

You may also be interested in...



Claritin Hives Relief Approval Could Close Out Rx Product Line

Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19

Claritin Hives Relief Approval Could Close Out Rx Product Line

Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19

Claritin Hives Relief Approval Could Close Out Rx Product Line

Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS095751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel